Dermata Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Public

  • Employees
  • 8

Employees

  • Stock Symbol
  • DRMA

Stock Symbol

  • Share Price
  • $0.76
  • (As of Friday Closing)

Dermata General Information

Description

Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.

Contact Information

Website
www.dermatarx.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
NAS
Primary Office
  • 3525 Del Mar Heights Road
  • Suite 322
  • San Diego, CA 92130
  • United States
+1 (858) 000-0000

Dermata Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Dermata Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.76 $0.75 $0.56 - $8.64 $2.38M 3.19M 216K -$4.42

Dermata Financials Summary

In Thousands,
USD 		TTM 30-Sep-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV (5,058) (3,117) 1,888
Revenue 0 0 0 0
EBITDA (7,534) (9,674) (7,857) (3,039)
Net Income (7,330) (9,611) (7,902) (3,237)
Total Assets 7,323 6,944 11,624 605
Total Debt 0 0 0 3,546
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Dermata Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Dermata‘s full profile, request access.

Request a free trial

Dermata Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commerc
Drug Discovery
San Diego, CA
8 As of 2022
000.00
00000000 000.00

000000

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu
0000 000000000
Boston, MA
00 As of 0000
00000
0000000000 0 00000

000000

laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in repre
0000 000000000
Perth, Australia
0 As of 0000
000.00
000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Dermata Competitors (32)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Centrexion Therapeutics Venture Capital-Backed Boston, MA 00 00000 0000000000 0 00000
0000000 0000000000 Corporation Perth, Australia 0 000.00 000000000 000.00
0000 000000000000 Formerly VC-backed Bridgewater, NJ 00 00000 000000000 00000
000-000 0000000000 Formerly PE-Backed Ness Ziona, Israel 00 00000 000000000 00000
0000000 000000 Venture Capital-Backed Barcelona, Spain 00 000.00 00000 00000
You’re viewing 5 of 32 competitors. Get the full list »

Dermata Patents

  • 16

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 16

    Pending

  • 000

    Expiring in next 12 mo

Dermata Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220175660-A1 Compositions for the treatment of skin conditions Pending 09-Dec-2020 000000000 0
EP-4267163-A1 Compositions for the treatment of skin conditions Pending 09-Dec-2020 000000000
CA-3204909-A1 Compositions for the treatment of skin conditions Pending 09-Dec-2020 000000000
AU-2021394765-A1 Compositions for the treatment of skin conditions Pending 09-Dec-2020 000000000
AU-2020315876-A1 Compositions for the treatment of conditions by dermal fillers Pending 23-Jul-2019 A61K35/614
To view Dermata’s complete patent history, request access »

Dermata Executive Team (8)

Name Title Board Seat Contact Info
Gerald Proehl Co-Founder, Chief Executive Officer, Chairman & President
Kyri Van Hoose Chief Financial Office & Senior Vice President
Christopher Nardo Ph.D Executive & Senior Vice President
Maria Bedoya Toro Munera Ph.D Senior Vice President
Warren Hall Senior Vice President, Product Development and Manufacturing
You’re viewing 5 of 8 executive team members. Get the full list »

Dermata Board Members (6)

Name Representing Role Since
Andrew Sandler MD Self Board Member 000 0000
David Hale Dermata Founder & Board Member 000 0000
Kathleen Scott Self Board Member 000 0000
Mary Fisher Self Board Member 000 0000
Steven Mento Ph.D Self Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Dermata Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Dermata Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Dermata‘s full profile, request access.

Request a free trial